The difference between domestically produced and imported avatrombopag

Avatrombopag (Avatrombopag, trade name Sucoxin, is an oral small molecule thrombopoietin receptor agonist, mainly used to treat thrombocytopenia related to chronic liver disease (CLD) and chronic immune thrombocytopenia (ITP), etc. It stimulates the proliferation and differentiation of megakaryocytes in the bone marrow by simulating the effects of natural thrombopoietin (TPO), thereby increasing platelet production and reducing the risk of bleeding.

On the market, there are both imported and domestic versions of avatrombopag, which differ in many aspects.

From a research and development background, imported avatrombopag usually refers to the original drug, which was developed by AkaRx Inc in the United States and was first launched on the market. Original drugs have invested a lot of money, time and manpower in the research and development process, so they have independent patent rights and intellectual property rights. Domestic Avatrombopag is a generic drug. After the patent protection period of the original drug expires, domestic pharmaceutical companies will copy and produce it based on the chemical composition, pharmacological effects, indications, administration routes and dosage of the original drug.

In terms of production technology and quality control, there are also differences between imported original drugs and domestic generic drugs. The original drug company has proprietary technology in the production process, strict quality control, and adopts higher process standards and raw material screening. Although domestic generic drugs also need to meet the strict standards of the drug regulatory authorities, including bioequivalence testing, the specific production processes and excipient formulas may be different from the original drugs, and the quality control systems may also be different.

In terms of price, imported original drugs usually have higher prices due to high research and development costs. Domestic generic drugs save most of the initial research and development costs, so the price is relatively low, and they are more suitable for patients who use large doses for a long time and patients with financial difficulties.

In addition, it is worth noting that whether it is an imported original drug or a domestic generic drug, it needs to be used under the guidance of a doctor to ensure the safety and effectiveness of the drug. At the same time, patients should pay close attention to the adverse reactions of the drug and changes in their own condition during use. If they have any symptoms of discomfort, they should seek medical treatment in time and inform the doctor of the drugs they are using.

AvatrombopagIt has been officially launched in the country and has been included in the reimbursement scope of medical insurance. Currently, there are two main options on the market: the original research version and the domestic imitation version. The specifications are 20 mg and 15 tablets per box. After being reimbursed by medical insurance, the price of the original research version fluctuates around 4,000 yuan, and the price of the domestic imitation version also exceeds 3,000 yuan. However, it is worth mentioning that there are lower-priced generic versions of avatrombopag in overseas markets, and the 28-tablet version only costs about 600 yuan, with a significant price gap.

In summary, there are differences between the domestic and imported versions of avatrombopag in terms of research and development background, production technology, quality control and price. Patients should make their decision based on doctor's advice, their own financial situation and consideration of drug quality when making their choice.